Gabapentin in Treating Peripheral Neuropathy in Cancer Patients Undergoing Chemotherapy

PHASE3CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

February 28, 2002

Primary Completion Date

November 30, 2007

Study Completion Date

November 30, 2007

Conditions
NeurotoxicityPain
Interventions
DRUG

gabapentin

OTHER

placebo

Trial Locations (23)

29303

CCOP - Upstate Carolina, Spartanburg

32224

Mayo Clinic, Jacksonville

48106

CCOP - Michigan Cancer Research Consortium, Ann Arbor

54301

CCOP - St. Vincent Hospital Cancer Center, Green Bay, Green Bay

55805

CCOP - Duluth, Duluth

55905

Mayo Clinic Cancer Center, Rochester

56303

CentraCare Health Plaza, Saint Cloud

57104

CCOP - Sioux Community Cancer Consortium, Sioux Falls

57709

Rapid City Regional Hospital, Rapid City

58201

Altru Cancer Center, Grand Forks

61602

CCOP - Illinois Oncology Research Association, Peoria

61801

CCOP - Carle Cancer Center, Urbana

68106

CCOP - Missouri Valley Cancer Consortium, Omaha

70121

CCOP - Ochsner, New Orleans

74136

CCOP - Oklahoma, Tulsa

85259-5404

CCOP - Mayo Clinic Scottsdale Oncology Program, Scottsdale

52403-1206

CCOP - Cedar Rapids Oncology Project, Cedar Rapids

50309-1016

CCOP - Iowa Oncology Research Association, Des Moines

51101-1733

Siouxland Hematology-Oncology, Sioux City

67214-3882

CCOP - Wichita, Wichita

58501-5505

Medcenter One Health System, Bismarck

43623-3456

CCOP - Toledo Community Hospital, Toledo

S4T 7T1

Allan Blair Cancer Centre, Regina

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Alliance for Clinical Trials in Oncology

OTHER

NCT00027963 - Gabapentin in Treating Peripheral Neuropathy in Cancer Patients Undergoing Chemotherapy | Biotech Hunter | Biotech Hunter